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malleable blades were easily adjusted to accommodate variability
in left atrial size and orientation of the pulmonary veins.
Comment
Development of new operative procedures has caused a resurgence
in the surgical treatment of atrial fibrillation. Like the Cox maze
procedure, these new operations generally include isolation of the
pulmonary veins and excision of the left atrial appendage. Expo-
sure of these structures, particularly in a large left atrium, is
challenging.
A series of new atrial retractor blades (Kapp Surgical Inc,
Cleveland, Ohio) provides exposure of the posterior left atrium and
pulmonary vein orifices. These blades, which are malleable and
universally adjustable, attach to a standard mitral valve retractor.
This system provides excellent and consistent exposure of the
posterior left atrium and pulmonary veins without the need for
surgical assistance, facilitating operations for atrial fibrillation.
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Zurich, Switzerland
The use of platelet aggregation agents, such as aspirin,glycoprotein IIb and IIIa inhibitors, and clopidogrel, hasincreased in recent years for patients with acute coro-nary syndromes, not least because of the results of the
Clopidogrel in Unstable Angina to Prevent Recurrent Events
study.1 In that study, clopidogrel significantly reduced the risk of
cardiovascular death, myocardial infarction, strokes, and other
related ischemic events in patients with acute coronary syndromes.
Clopidogrel demonstrated benefits that were incremental to and
independent of other therapies that the patients might have re-
ceived, such as anticoagulants, angiotensin-converting enzyme
inhibitors, -blockers, and lipid-lowering agents. The study also
confirmed the synergistic effect of the modes of action of clopi-
dogrel and aspirin; clopidogrel inhibits adenosine 5'-diphosphate–
induced platelet aggregation, whereas aspirin inhibits cyclooxy-
genase and reduces thromboxane A2. The obvious inference from
these findings is that all patients with an acute coronary syndrome
should benefit from the favorable effects of clopidogrel, without
exception and without delay, if possible in the prehospital period.
In this case, patients who have not had the opportunity to undergo
coronary angiography with subsequent PCI and who are dependent
on thrombolytic therapy, as well as those who require an urgent
surgical revascularization, would also be treated with clopidogrel.
This raises the question of indications and appropriateness of
clopidogrel administration during the immediate preoperative
course.
Clinical Summary
During a 12-month period (February 2001–January 2002), we
performed 268 isolated coronary artery bypass grafts at our insti-
tution. For patients receiving clopidogrel medication, elective sur-
gery was postponed at least 10 days after stopping clopidogrel. Of
the 268 patients, however, 13 (4.8%) (8 men, 5 women, mean age
68 years) required urgent operation after clopidogrel administra-
tion. All patients had an acute coronary syndrome and had received
clopidogrel already before hospitalization (before coronary an-
giography). In 6 patients (group A), coronary artery bypass graft-
ing was performed within 24 hours of hospitalization because of
hemodynamic instability or critical coronary anatomy. These pa-
tients all received an intra-aortic balloon pump, a -blocker, aspi-
rin, and heparin. The remaining patients (group B) were operated
after at least 7 days of clopidogrel. During this time they received
aspirin, heparin, and a -blocker, as well as initial treatment with
glycoprotein IIb and IIIa inhibitor, but no clopidogrel. Of the 13
operations, 11 were performed without extracorporeal circulation.
There were no deaths in this small series. However, there was a
statistically significant difference between the two groups with
respect to the need for transfusions of packed red blood cells,
fresh-frozen plasma, and platelets (Table 1). In addition, 2 of the
6 patients who were operated on while receiving clopidogrel
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(group A) required reexploration for bleeding within 12 hours after
the operation.
Discussion
Our experience shows that failure to stop clopidogrel at least 7
days before surgery in patients with acute coronary syndrome
necessitating urgent surgical revascularization resulted in unac-
ceptable rates of transfusion and reexploration for bleeding, re-
gardless of the surgical technique used (on- or off-pump surgery).
Transfusion of blood and blood products exposes patients to trans-
fusion-related complications, and reexploration related to bleeding
has been shown to increase hospital stay and to be associated with
an increase in mortality.2 Bleeding after surgery is usually multi-
factorial; however, coagulation disorders or platelet abnormalities,
either alone or in combination, are the most probable reasons for
bleeding in patients receiving aggressive treatment for acute cor-
onary syndrome. The use of aprotinin has significantly reduced
rates of reexploration and excessive bleeding,3 but nothing is
known about hemostatic effects with clopidogrel.
For patients with an acute coronary syndrome necessitating
surgical revascularization, the benefits of antiplatelet therapy in
reducing mortality and decreasing myocardial ischemia must be
carefully weighed against the risk of bleeding. Clopidogrel has an
irreversible effect on platelet function for the entire life span of
each individual platelet. Thus once the drug has been discontinued,
recovery of overall platelet function will be delayed for several
days until a significant number of new platelets have been pro-
duced and released. In contrast, glycoprotein IIb and IIIa inhibi-
tors, especially tirofiban, have a short half-life that permits emer-
gency operation without an increased risk of bleeding.4 We are
therefore convinced that routine out-of-hospital administration of
clopidogrel should not be recommended for all patients with acute
coronary syndrome. Risk stratification and balancing the therapeu-
tic possibilities for individual patients at any time and place is
mandatory for optimizing therapy. Clopidogrel should be given
only to those patients who do not need or are not eligible for urgent
surgery. For patients receiving clopidogrel, discontinuation of this
drug and postponing surgery if possible can reduce postoperative
bleeding.
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TABLE 1. Intraoperative and postoperative transfusions af-
ter coronary artery bypass grafting in patients who were
receiving clopidogrel or had had clopidogrel discontinued
at least 7 days previously
Transfusions
Group A
(procedure with
clopidogrel)
Group B (clopidogrel
stopped >7 d before
procedure)
P
value
Packed red blood
cells (units)
10.8 1.7 .01
Fresh-frozen
plasma (units)
7.7 1.7 .01
Platelets (units) 9.0 0.2 .01
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